|
2024
|
Invention
|
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder.
Treatment of non 24 sleep... |
|
|
Invention
|
Methods and compositions for treatment of epileptic disorders.
Use of allosteric modulators and/... |
|
|
Invention
|
Methods of increasing tonic inhibition and treating secondary insomnia.
Methods of increasing to... |
|
|
Invention
|
Rnai targeting hnrnph2 missense mutations for treatment of bain syndrome.
RNAi involving siRNA o... |
|
|
Invention
|
Kif1a missense mutations for treatment of kif1a associated neurological disorder. KIF1AKIF1AcisKI... |
|
|
Invention
|
Hnrnph2 missense mutations for treatment of bain syndrome. HNRNPH2 HNRNPH2 for treatment of Bain ... |
|
|
Invention
|
Rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder. ... |
|
|
Invention
|
Rnai targeting ppp2r5d missense mutations for treatment of jordan’s syndrome.
RNAi involving siR... |
|
|
Invention
|
Ppp2r5d missense mutations for treatment of jordan's syndrome. PPP2R5DPPP2R5D alleles containing ... |
|
|
Invention
|
Pharmaceutical formulations containing gaboxadol for therapeutic treatment.
Pharmaceutical formu... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of m... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal t... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of di... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of r... |
|
|
Invention
|
Methods of treating seizure disorders and prader-willi syndrome.
Methods of treating a seizure d... |
|
2023
|
Invention
|
Methods and compositions for treatment of epileptic disorders. Use of allosteric modulators and/o... |
|
|
Invention
|
Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of ca... |
|
|
Invention
|
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds... |
|
|
Invention
|
Shrna targeting snord115 locations to restore paternal ube3a gene expression in angelman syndrome... |
|
|
Invention
|
Shrna targeting ube3a-ats to restore paternal ube3a gene expression in angelman syndrome.
Provid... |
|
|
Invention
|
Shrna targeting snord115 locations to restore paternal ube3a gene expression in angelman syndrome |
|
|
Invention
|
Shrna targeting ube3a-ats to restore paternal ube3a gene expression in angelman syndrome. Provide... |
|
|
Invention
|
Shrna targeting ube3a-ats to restore paternal ube3a gene expression in angelman syndrome. UBE3A-A... |
|
|
Invention
|
Snord115 locations to restore paternal ube3a gene expression in angelman syndrome. SNORD115UBE3A-... |
|
2022
|
Invention
|
Methods of treating developmental disorders with gaboxadol.
Methods of treating developmental di... |
|
|
Invention
|
Use of gaboxadol in the treatment of substance use disorders.
Methods of using gaboxadol or a ph... |
|
2021
|
Invention
|
Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders.
Use of gaboxadol,... |
|
|
G/S
|
Research and development of therapies for the treatment of diseases and disorders |
|
|
Invention
|
Treatment of depressive disorders.
Formulations for treating depressive disorders and methods fo... |
|
|
Invention
|
Recombinant adeno-associated vectors.
Adeno-associated virus (AAV) vectors and uses thereof are ... |
|
|
Invention
|
Methods of treating attention deficit hyperactivity disorder.
Methods and compositions for treat... |
|
|
Invention
|
Methods of treating seizure disorders and prader-willi syndrome. Methods of treating a seizure di... |
|
2020
|
Invention
|
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome. Methods and pharmaceutical composi... |
|
2019
|
G/S
|
Psychological assessment services; psychological testing; psychiatric testing; Psychiatric servic... |
|
2017
|
G/S
|
Pharmaceutical product evaluation for the treatment of rare neurological diseases and disorders; ... |
|
|
G/S
|
Pharmaceutical research and development |
|
|
G/S
|
Pharmaceutical research and development. |
|
2015
|
G/S
|
pharmaceutical research and development for the treatment of rare neurological diseases and diso... |
|
|
G/S
|
Pharmaceutical product evaluation * for the treatment of rare neurological diseases and disorders... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of diseases, conditions and disorders of the brain.... |
|
|
G/S
|
Pharmaceutical research and development of therapies for rare neurological diseases of the brain. |
|
2014
|
G/S
|
Pharmaceutical Research and Development of therapies for * rare neurological * diseases of the brain |
